WuXi XDC and LigaChem Expand Partnership to Advance ADC Development
Wednesday, February 26, 2025
WuXi XDC Cayman has expanded its collaboration with LigaChem Biosciences through a new Memorandum of Understanding (MOU).
This agreement broadens the scope of their partnership, aiming to accelerate the development of innovative ADC therapies for cancer and other serious diseases.
Under the expanded MOU, WuXi XDC’s integrated ADC discovery service platform will support LigaChem’s research and development efforts, enhancing efficiency and speeding up the progression of ADC candidates from discovery to development.
By leveraging WuXi XDC’s advanced technologies and expertise, LigaChem is expected to benefit from a more streamlined process at all stages of ADC development.
LigaChem will also utilise WuXi XDC’s manufacturing platform to advance multiple ADC projects. This expansion reinforces both companies’ commitment to developing innovative therapies that address critical medical needs.
The collaboration between WuXi XDC and LigaChem began in 2021 and has since led to significant progress in ADC and bioconjugate innovation.
This latest agreement strengthens their shared goal of advancing next-generation ADC therapies, with the potential to bring meaningful benefits to patients worldwide.
Source: wuxixdc.com
